Interleukin 3, Recombinant, Mouse (IL-3)

IL-3 is a hematopoietic growth factor that promotes the survival, differentiation and proliferation of committed progenitor cells of the megakaryocyte, granulocyte-macrophage, erythroid, eosinophil, basophil and mast cell lineages. Produced by T cells, mast cells and eosinophils, IL-3 enhances thrombopoieses, phagocytosis, and antibody-mediated cellular cytotoxicity. Its ability to activate monocytes suggests that IL-3 may have additional immunoregulatory roles. Many of the IL-3 activities depend upon co-stimulation with other cytokines. IL-3 is species-specific, variably glycosylated cytokine. Recombinant murine IL-3 is a 15.1kD globular protein containing 135 amino acid residues.\n\nBiological Activity: \nThe ED50 as determined by the dose-dependent stimulation of the proliferation of murine M-NFS-60 cells is \n(same/less than) 0.05ng/ml, corresponding to a specific activity of (same/more than) 2 x 10e7u/mg.\n\nAA Sequence: \nMDTHRLTRTL NCSSIVKEII GKLPEPELKT DDEGPSLRNK SFRRVNLSKF VESQGEVDPE DRYVIKSNLQ KLNCCLPTSA NDSALPGVFI RDLDDFRKKL RFYMVHLNDL ETVLTSRPPQ PASGSVSPNR GTVEC\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile buffer or ddH2O and carrier protein (0.1% HSA or BSA). Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.\n\nCountry of Origin: USA

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7663-36

Size

2ug

Form

Supplied as a lyophilized protein without additives. Reconstitute with sterile dH2O to a concentration of 0.1-1.0mg/ml.

Purity

Highly Purified (~ 98% by SDS-PAGE analysis).\nEndotoxin: (same/less than) 0.1ng/ug (1EU/ug).

References

1. Chandra, S., et al., A rare complex DNA rearrangement in the murine Steel gene results in exon duplication and a lethal phenotype. Blood 102: 3548-3555. 2. Marrow, M., et al., TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 103: 3890-3896 (2004). 3. Samson, S.I., et al., Combined deficiency in IkappaBalpha and IkappaBepsilon reveals a critical window of NF-kappaB activity in natural killer cell differentiation. Blood 103: 4573-4580 (2004). 4. Zhu, Quan-Sheng, et al., G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood 103: 3305-3312 (2004). 5. Perry, S.S., et al., L-selectin defines a bone marrow analog to the thymic early T-lineage progenitor. Blood 103: 2990-2996 (2004). 6. Kamata, T., et al., Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood 103: 2568-2570 (2004). 7. Loh, M.L., et al., Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325-2331 (2004). 8. Schnurr, M., et al., Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 103: 1391-1397 (2004). 9. Klarmann, K., et al., Identification of in vitro growth conditions for c-Kit-negative hematopoietic stem cells. Blood 102: 3120-3128 (2004). 10. Kamata, T., et al., Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood (2004) 103: 2568-2570. 11. Nemeth, M.J., et al., Hmgb3: an HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation. Blood 102: 1298-1306 (2003). 12. Shivakrupa, R., et al., Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Research 63: 4412-4449 (2003). 13. Peltola, K.J., et al., Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103: 3744-3750 (2003). 14. Sohal, J., et al., A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101: 3188-3197 (2003).